Current role
Carlos A. Trujillo
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Carlos A. Trujillo
PharmaCyte Biotech, Inc. reported in an 8-K filed August 16, 2022 that Carlos A. Trujillo resigned as member of the Board, effective August 15, 2022. The proxy statement of PharmaCyte Biotech, Inc. reports total compensation of $482,017 for Carlos A. Trujillo in fiscal 2025, including a base salary of $380,000. Disclosed compensation is on record for 5 fiscal years.
“effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
PharmaCyte Biotech, Inc. (PMCB)
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at PharmaCyte Biotech, Inc.
Other people whose current roles at this company are on record from its filings.
- Joshua N. Silverman CEO, Chairman, Board Member
- Joshua Silverman CEO
- Gerald W. Crabtree CTO
- Daniel Allen Board Member
- Jack E. Stover Board Member
- Jonathan L. Schechter Board Member
- Michael M. Abecassis Board Member
- Robert Weinstein Board Member
- Wayne R. Walker Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | PharmaCyte Biotech, Inc. (PMCB) | Officer | $380,000 | $482,017 |
| 2024 | PharmaCyte Biotech, Inc. (PMCB) | Officer | $380,000 | $636,118 |
| 2023 | PharmaCyte Biotech, Inc. (PMCB) | — | $380,000 | $385,259 |
| 2022 | PharmaCyte Biotech, Inc. (PMCB) | — | $485,577 | $631,851 |
| 2021 | PharmaCyte Biotech, Inc. (PMCB) | — | $300,000 | $422,114 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.